<DOC>
	<DOCNO>NCT00885755</DOCNO>
	<brief_summary>This single arm study evaluate alteration molecular marker expression HER2-positive target therapy , evaluate effect continue treatment Herceptin Xeloda beyond progression follow initial Herceptin-taxane chemotherapy . Patients develop progressive disease receive first-line Herceptin ( 8mg/kg iv load dose 6mg/kg iv every 3 week ) + taxane therapy . patient develop progressive disease within 9 week treatment continue treatment Herceptin combination Xeloda ( 1000mg/m2 po bid day 1-14 3-week cycle ) .Biopsies tumor tissue take biomarker gene profile evaluation . The anticipated time study treatment disease progression , intolerable side effect patient choice , target sample size 100 individual .</brief_summary>
	<brief_title>A Study Herceptin ( Trastuzumab ) Biomarkers Patients With HER2-Positive Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Taxane</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>female patient , &gt; =18 year age ; HER2positive breast cancer ; al least one metastatic site amenable core biopsy ; leave ventricular ejection fraction &gt; 50 % . prior adjuvant/neoadjuvant Herceptin within past 6 month ; prior adjuvant taxane therapy within past 12 month ; use chemotherapy , immunotherapy biological anticancer therapy within past 3 week ; know bleeding diatheses .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>